Table Info

Table 1.

Recently approved targeted therapies to treat patients with advanced or metastatic TNBC (PARP inhibitors, immune checkpoint inhibitors, and antibody-drug conjugate)

Therapeutic target	Treatment class Drug/combination	RCT (phase 3) identifier	Therapeutic considerations	Author, year, reference
ADP ribose polymerase PARP 1	PARP1 inhibitor olaparib	OlympiAD NCT02000622	In the OlympiAD study, olaparib has improved PFS compared with CHT of physician's choice, among pts with a gBRCA1/2 mutation & HER2-negative metastatic BC	Robson et al. 2019 [29]
ADP ribose polymerase PARP	PARP inhibitor talazoparib	EMBRACA NCT01945775	In the EMBRACA trial, talazoparib prolonged PFS vs. CHT & improved PRO in gBRCA1/2-mutated ABC	Litton et al. 2020 [30]
PD-L1	Anti-PD-L1 monoclonal antibody atezolizumab + nab-paclitaxel (CHT)	IMpassion130 NCT02425891	In the 2nd interim OS analysis of the IMpassion130 trial, no significant difference in OS between the treatment groups in the ITT population was reported, but a clinically meaningful OS benefit with atezolizumab + nab-paclitaxel in pts with PD-L1 immune cell-positive disease was noted. In pts with PD-L1 immune cell-positive metastatic TNBC, atezolizumab + nab-paclitaxel is a valid therapeutic option	Schmid et al. 2020 [31]
PD-1	Anti-PD-1 monoclonal antibody pembrolizumab + CHT	KEYNOTE-355 NCT02819518	Pembrolizumab-CHT revealed a clinically meaning- ful improvement in PFS vs. placebo-CHT, in pts with metastatic TNBC (CPS ≥ 10); such results suggest that the addition of pembrolizumab to standard CHT for the 1-st-line treatment of metastatic TNBC is beneficial	Cortes et al. 2020 [32]
The human (Trop-2)	Antibody-drug conjugate sacituzumab govitecan-hziy [a combination of a monoclonal antibody, targeting Trop-2 with SN-38 (a cytotoxic, potent topoisomerase I inhibitor; a metabolite of irinotecan, conjugated to the antibody by a cleavable linker)]	IMMU-132-01 NCT01631552	Sacituzumab govitecan-hziy was associated with durable objective responses in pts with heavily pretreated metastatic TNBC	Bardia et al. 2019 [33]

ABC: advanced breast cancer; CPS: combined positive score; g: germline; ITT: intention-to-treat; PFS: progression-free survival; pts: patients; PRO: patient-reported outcomes; RCT: randomized controlled trial

Declarations

Author contributions

The author contributed solely to the work.

Conflicts of interest

The author declares that she has no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Siddharth S, Sharma D. Racial disparity and triple-negative breast cancer in African-American women: a multifaceted affair between obesity, biology, and socioeconomic determinants. Cancers (Basel). 2018;10:1–19. [DOI] [PubMed] [PMC]

Willett K, Jiang R, Lenart E, Spiegelman D, Willett W. Comparison of bioelectrical impedance and BMI in predicting obesity-related medical conditions. Obesity (Silver Spring). 2006;14:480–90. [DOI] [PubMed]

Denis GV, Palmer JR. “Obesity-associated” breast cancer in lean women: metabolism and inflammation as critical modifiers of risk. Cancer Prev Res (Phila). 2017;10:267–9. [DOI] [PubMed] [PMC]

Gallagher EJ, Fei K, Feldman SM, Port E, Friedman NB, Boolbol SK, et al. Insulin resistance contributes to racial disparities in breast cancer prognosis in US women. Breast Cancer Res.2020;22:40. [DOI] [PubMed] [PMC]

Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176–98. [DOI] [PubMed] [PMC]

Yedjou CG, Sims JN, Miele L, Noubissi F, Lowe L, Fonseca DD, et al. Health and racial disparity in breast cancer. Adv Exp Med Biol. 2019;1152:31–49. [DOI] [PubMed] [PMC]

Evans J, Goedecke JH, Söderström I, Burén J, Alvehus M, Blomquist C, et al. Depot- and ethnic-specific differences in the relationship between adipose tissue inflammation and insulin sensitivity. Clin Endocrinol (Oxf). 2011;74:51–9. [DOI] [PubMed]

Park NJ, Kang DH. Inflammatory cytokine levels and breast cancer risk factors: racial differences of healthy Caucasian and African American women. Oncol Nurs Forum. 2013;40:490–500. [DOI] [PubMed]

Iyengar NM, Brown KA, Zhou XK, Gucalp A, Subbaramaiah K, Giri DD, et al. Metabolic obesity, adipose inflammation and elevated breast aromatase in women with normal body mass index. Cancer Prev Res (Phila). 2017;10:235–43. [DOI] [PubMed] [PMC]

10.

Bandera EV, Chandran U, Hong CC, Troester MA, Bethea TN, Adams-Campbell LL, et al. Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium. Breast Cancer Res Treat. 2015;150:655–66. [DOI] [PubMed] [PMC]

11.

Walsh T, Gulsuner S, Lee MK, Troester MA, Olshan AF, Earp HS, et al. Inherited predisposition to breast cancer in the Carolina Breast Cancer Study. NPJ Breast Cancer. 2021;7:6. [DOI] [PubMed] [PMC]

12.

Bandera EV, Chandran U, Zirpoli G, Gong Z, McCann SE, Hong CC, et al. Body fatness and breast cancer risk in women of African ancestry. BMC Cancer. 2013;13:475. [DOI] [PubMed] [PMC]

13.

Griffith KA, Chung SY, Zhu S, Ryan AS. Insulin resistance and inflammation in black women with and without breast cancer: cause for concern. Ethn Dis. 2016;26:513–20. [DOI] [PubMed] [PMC]

14.

Stewart PA, Luks J, Roycik MD, Sang QA, Zhang J. Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer. PLoS One. 2013;8:e82460. [DOI] [PubMed] [PMC]

15.

Bandera EV, Demissie K, Qin B, Llanos AAM, Lin Y, Xu B, et al. The Women’s Circle of Health Follow-Up Study: a population-based longitudinal study of black breast cancer survivors in New Jersey. J Cancer Surviv. 2020;14:331–46. [DOI] [PubMed] [PMC]

16.

Capers PL, Kinsey AW, Miskell EL, Affuso O. Visual representation of body shape in African-American and European American women: clinical considerations. Clin Med Insights Womens Health. 2016;9:63–70. [DOI] [PubMed] [PMC]

17.

Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–69. [DOI] [PubMed] [PMC]

18.

Qian B, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51. [DOI] [PubMed] [PMC]

19.

Medrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012;12:306. [DOI] [PubMed] [PMC]

20.

Yao S, Cheng TD, Elkhanany A, Yan L, Omilian A, Abrams SI, et al. Breast tumor microenvironment in black women: a distinct signature of CD8⁺ T-cell exhaustion. J Natl Cancer Inst. 2021;113:1036–43. [DOI] [PubMed]

21.

Sineshaw HM, Gaudet M, Ward EM, Flanders WD, Desantis C, Lin CC, et al. Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010–2011). Breast Cancer Res Treat. 2014;145:753–3. [DOI] [PubMed]

22.

Williams DR, Mohammed SA, Shields AE. Understanding and effectively addressing breast cancer in African American women: unpacking the social context. Cancer. 2016;122:2138–49. [DOI] [PubMed] [PMC]

23.

Chu QD, Henderson AE, Ampil F, Li BDL. Outcome for patients with triple-negative breast cancer is not dependent on race/ethnicity. Int J Breast Cancer. 2012;2012:764570. [DOI] [PubMed] [PMC]

24.

Hossain F, Danos D, Prakash O, Gilliland A, Ferguson TF, Simonsen N, et al. Neighborhood social determinants of triple negative breast cancer. Front Public Health. 2019;7:18. [DOI] [PubMed] [PMC]

25.

Bhattarai S, Saini G, Gogineni K, Aneja R. Quadruple-negative breast cancer: novel implications for a new disease. Breast Cancer Res. 2020;22:127. [DOI] [PubMed] [PMC]

26.

Saini G, Bhattarai S, Gogineni K, Aneja R. Quadruple-negative breast cancer: an uneven playing field. JCO Glob Oncol. 2020;6:233–7. [DOI] [PubMed] [PMC]

27.

Dietze EC, Chavez TA, Seewaldt VL. Obesity and triple-negative breast cancer: disparities, controversies, and biology. Am J Pathol. 2018;188:280–90. [DOI] [PubMed] [PMC]

28.

Gupta GK, Collier AL, Lee D, Hoefer RA, Zheleva V, Siewertsz van Reesema LL, et al. Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers (Basel). 2020;12:2392. [DOI] [PubMed] [PMC]

29.

Robson ME, Tung N, Conte P, Im S, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558–66. [DOI] [PubMed] [PMC]

30.

Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee K, Gonçalves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31:1526–35. [DOI] [PubMed]

31.

Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Onl. 2020;21:44–59. [DOI] [PubMed]

32.

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–28. [DOI] [PubMed]

33.

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–51. [DOI] [PubMed]

34.

Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN, Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136:331–45. [DOI] [PubMed] [PMC]

35.

Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, et al. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol. 2017;3:509–15. [DOI] [PubMed]

36.

Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, et al. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol. 2017;28:754–60. [DOI] [PubMed]

37.

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O’Shaughnessy J, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36:884–90. [DOI] [PubMed] [PMC]

38.

Austin D, Hamilton N, Elshimali Y, Pietras R, Wu Y, Vadgama J. Estrogen receptor-beta is a potential target for triple negative breast cancer treatment. Oncotarget. 2018;9:33912–30. [DOI] [PubMed] [PMC]

39.

Rubinstein MM, Brown KA, Iyengar NM. Targeting obesity-related dysfunction in hormonally driven cancers. Br J Cancer. 2021;125:495–509. [DOI] [PubMed] [PMC]

40.

Rigiracciolo DC, Nohata N, Lappano R, Cirillo F, Talia M, Scordamaglia D, et al. IGF-1/IGF-1R/FAK/YAP transduction signaling prompts growth effects in triple-negative breast cancer (TNBC) cells. Cells. 2020;9:1010. Erratum in: Cells. 2020;9:2619. [DOI] [PubMed] [PMC]

41.

Obr AE, Kumar S, Chang Y, Bulatowicz JJ, Barnes BJ, Birge RB, et al. Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment. Breast Cancer Res. 2018;20:138. [DOI] [PubMed] [PMC]

42.

Farabaugh SM, Boone DN, Lee AV. Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation. Front Endocrinol (Lausanne). 2015;6:59. [DOI] [PubMed] [PMC]

43.

Singh SK, Tan QW, Brito C, De León M, De León D. Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women. Growth Horm IGF Res. 2010;20:245–54. [DOI] [PubMed] [PMC]

44.

Montesdeoca N, López M, Ariza X, Herrero L, Makowski K. Inhibitors of lipogenic enzymes as a potential therapy against cancer. FASEB J. 2020;34:11355–81. [DOI] [PubMed]